What are the recommended dosing regimens, contraindications, baseline laboratory tests, monitoring schedule, and criteria for discontinuation of upadacitinib (Rinvoq) for its approved indications?

Upadacitinib (Rinvoq) Dosing and Management

Recommended Dosing Regimens

The dosing of upadacitinib varies significantly by indication, with most conditions requiring 15 mg once daily for maintenance, while inflammatory bowel disease requires higher induction doses of 45 mg daily. 1

By Indication:

Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis:

• Adults: 15 mg once daily 1
• Pediatric PsA (≥30 kg): 15 mg once daily or 6 mg oral solution twice daily 1
• Pediatric PsA (20-30 kg): 4 mg oral solution twice daily 1
• Pediatric PsA (10-20 kg): 3 mg oral solution twice daily 1

Atopic Dermatitis:

• Adults <65 years: Start 15 mg once daily; may increase to 30 mg once daily if inadequate response 1
• Adults ≥65 years: 15 mg once daily maximum 1
• Discontinue if inadequate response to 30 mg dose 1

Ulcerative Colitis:

• Induction: 45 mg once daily for 8 weeks 1, 2
• Maintenance: 15 mg once daily 1
• May use 30 mg once daily for refractory, severe, or extensive disease 1
• Discontinue if inadequate response to 30 mg maintenance dose 1

Crohn's Disease:

• Induction: 45 mg once daily for 12 weeks 1
• Maintenance: 15 mg once daily 1
• May use 30 mg once daily for refractory, severe, or extensive disease 1

Polyarticular Juvenile Idiopathic Arthritis:

• Same weight-based dosing as pediatric psoriatic arthritis 1

Contraindications

Upadacitinib is contraindicated only in patients with known hypersensitivity to upadacitinib or any excipients. 1 However, several clinical situations warrant extreme caution or avoidance:

Absolute Avoidance:

• Active serious infections (bacterial, fungal, viral, or opportunistic) 3, 1
• Untreated latent tuberculosis 3
• Severe hepatic impairment (Child-Pugh C) 3, 1

Relative Contraindications Requiring Careful Risk-Benefit Assessment:

• Active malignancy or recent malignancy (<5 years in most trials) 3
• Pregnancy and lactation (teratogenic in animal studies) 3
• Age ≥65 years with cardiovascular risk factors (particularly for tofacitinib, but caution extends to all JAK inhibitors) 3
• History of venous thromboembolism 4
• Multiple VTE risk factors (inherited thrombophilias, recent surgery, immobility, obesity, smoking, exogenous estrogen use) 4

Baseline Laboratory Tests and Assessments

Before initiating upadacitinib, perform comprehensive infectious disease screening, complete blood counts, liver function tests, lipid panel, and pregnancy testing in women of childbearing potential. 1

Required Baseline Testing:

• Tuberculosis screening: Tuberculin skin test or interferon-gamma release assay 3, 1
• Viral hepatitis screening: Hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody 1
• Complete blood count with differential: Assess absolute lymphocyte count (ALC), absolute neutrophil count (ANC), and hemoglobin 1
• Hepatic function panel: AST, ALT, bilirubin 1
• Lipid panel: Total cholesterol, LDL, HDL, triglycerides 1
• Renal function: Serum creatinine, estimated GFR 1
• Pregnancy test: For women of reproductive potential 3, 1

Additional Baseline Considerations:

• Update all immunizations, particularly live vaccines (must be completed before starting therapy) 1
• Assess cardiovascular risk factors 4
• Screen for history of malignancy 3
• Evaluate VTE risk factors 4

Monitoring Schedule

Monitor complete blood counts and liver enzymes every 3 months during treatment, with lipid panels assessed 12 weeks after initiation. 1

Laboratory Monitoring:

• Weeks 4-12: CBC with differential, hepatic function panel
• Week 12: Lipid panel
• Every 3 months thereafter: CBC with differential, hepatic function panel
• Periodically: Lipid panel, renal function

Clinical Monitoring:

• Assess for signs/symptoms of infection at each visit
• Monitor for skin changes (acne, rash, herpes zoster) 1
• Evaluate cardiovascular symptoms
• Screen for VTE symptoms (leg swelling, chest pain, dyspnea)
• Monitor disease activity and treatment response

Criteria for Discontinuation or Dose Interruption

Interrupt upadacitinib if ALC <500 cells/mm³, ANC <1000 cells/mm³, or hemoglobin <8 g/dL; discontinue permanently for serious infections, malignancy, or major adverse cardiovascular events. 1

Mandatory Interruption Thresholds:

• ALC <500 cells/mm³ 1
• ANC <1000 cells/mm³ 1
• Hemoglobin <8 g/dL 1
• Active serious infection 1

Permanent Discontinuation Indications:

• Serious hypersensitivity reaction (anaphylaxis) 1
• New malignancy diagnosis 3
• Major adverse cardiovascular event 1
• Venous thromboembolism 1
• Gastrointestinal perforation 1
• Inadequate therapeutic response at maximum approved dose 1

Dose Reduction Considerations:

• Sustained remission on background therapy may warrant dose reduction 3
• For atopic dermatitis, use lowest effective dose to maintain response 1
• For IBD, use lowest effective dose; if 30 mg maintenance fails, discontinue 1

Dose Adjustments for Special Populations

Renal Impairment:

• Severe renal impairment (eGFR 15-30 mL/min/1.73m²):
  • Atopic dermatitis: 15 mg once daily maximum 1
  • UC induction: 30 mg once daily for 8 weeks 1
  • UC maintenance: 15 mg once daily 1
  • CD induction: 30 mg once daily for 12 weeks 1
  • CD maintenance: 15 mg once daily 1
• End-stage renal disease (eGFR <15 mL/min/1.73m²): Not recommended 1
• Mild-moderate impairment: No adjustment needed for most indications 1

Hepatic Impairment:

• Severe (Child-Pugh C): Not recommended 1
• Mild-moderate (Child-Pugh A/B):
  • RA, PsA, AD, AS, nr-axSpA, pJIA: No adjustment 1
  • UC/CD induction: 30 mg once daily 1
  • UC/CD maintenance: 15 mg once daily 1

Drug Interactions:

• Strong CYP3A4 inhibitors (ketoconazole): Consider dose reduction 3
• Strong CYP3A4 inducers (rifampicin): Consider dose increase 3
• For RA, PsA, AS, nr-axSpA, pJIA: No formal dose adjustment required 1

Key Clinical Pitfalls

Do not combine upadacitinib with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants like azathioprine or cyclosporine. 1 This combination significantly increases infection risk without additional benefit.

Common Errors to Avoid:

• Starting therapy without TB screening or with untreated latent TB
• Failing to interrupt therapy when cytopenias develop
• Using in elderly patients with cardiovascular risk factors without careful consideration
• Combining with other immunosuppressants beyond conventional DMARDs
• Inadequate contraception counseling for reproductive-age patients
• Missing medication residue in stool (indicates malabsorption in short gut patients) 1
• Splitting, crushing, or chewing extended-release tablets 1

Safety Signals Requiring Vigilance:

The evidence shows serious infection rates comparable to adalimumab at standard doses, but higher rates in elderly patients with cardiovascular risk factors 3. Malignancy risk appears elevated in older RA patients based on the tofacitinib ORAL Surveillance trial 4, though AD-specific data show lower rates 4. VTE risk remains a concern across all JAK inhibitors, particularly in high-risk patients 4.